RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Health care resource use and medical costs attributable to respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States
A retrospective claims database analysis
Aris, E., Brabant, Y., La, E. M., Candrilli, S., & Molnar, D. (2023). Health care resource use and medical costs attributable to respiratory syncytial virus (RSV) among adults ≥60 years of age in the United States: A retrospective claims database analysis. Value in Health, 26(6), S124. https://doi.org/10.1016/j.jval.2023.03.657
Abstract EE356 Section snippets Objectives Annually, 3–7% of older adults in the United States (US) experience respiratory syncytial virus (RSV) infection. However, estimating the costs associated with RSV is challenging because of undertesting/underdiagnosis of RSV in clinical practice. The current study estimates RSV-related health care resource use and associated direct medical costs by highest level of care received among adults aged ≥60 years in the US.
Methods A retrospective observational study was conducted using administrative health insurance claims data from Optum's de-identified Clinformatics Data Mart Database (July 2016-June 2020). RSV cases were identified using ICD-10-CM diagnosis codes and were classified based on the highest level of care received during the episode (hospitalization, emergency department [ED] visit, or outpatient visit). Incremental all-cause health care costs were calculated over specified follow-up periods for
Results Overall, 12,704 diagnosed RSV episodes were observed during the study period. The incidence rate of medically-attended diagnosed RSV was 0.66 per 1,000 person-years, with rates increasing over the study period. Almost 91% of the episodes were classified as lower respiratory tract disease, and 67.9% of the cases were hospitalized, 13.2% resulted in an ED visit, and 18.9% resulted in an outpatient visit as the highest level of care received. A total of 7.7% of hospitalized RSV patients died
Conclusions RSV testing and reporting in the medical claims database is likely prioritized for severe cases resulting in a low estimated incidence rate. Despite this underreporting, the results of the current study highlight the substantial burden of RSV in adults aged ≥60 years. Funding: GlaxoSmithKline Biologicals SA (VEO-000322)